<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03645876</url>
  </required_header>
  <id_info>
    <org_study_id>SHR-1210-II-210</org_study_id>
    <nct_id>NCT03645876</nct_id>
  </id_info>
  <brief_title>SHR-1210 in Combination With BP102 and XELOX in Patient With Metastatic Colorectal Cancer</brief_title>
  <official_title>SHR-1210，a Novel Anti-pd-1 Antibody, in Combination With BP102,a Biosimilar of Bevacizumab, and XELOX, (Oxaliplatin Plus Capecitabine) in Patient With Metastatic Colorectal Cancer: a Single-arm, Open Label, Multi-center, Phase II Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open label, single-arm, multi-center, phase II study of SHR-1210 in metastatic&#xD;
      colorectal cancer patients with the recurrent lesion(s) post-surgery or the untreated mCRC.&#xD;
&#xD;
      SHR-1210 is a humanized monoclonal antibody against Programmed death 1(PD-1).BP102 is a&#xD;
      humanized recombinant monoclonal IgG1 antibody.&#xD;
&#xD;
      The primary objective of this study is to investigate the safety and efficacy of the subjects&#xD;
      who given the combination therapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The study was terminated early due to company decision&#xD;
  </why_stopped>
  <start_date type="Actual">November 8, 2018</start_date>
  <completion_date type="Actual">April 18, 2019</completion_date>
  <primary_completion_date type="Actual">April 18, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of the combination therapy: Number of Participants With Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment</measure>
    <time_frame>24 months</time_frame>
    <description>From sign icf to the end of follow-up</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>24 months</time_frame>
    <description>From sign icf to occurrence of objective response (complete regression (CR) and partial regression (PR) need to be confirmed 28 days after the occurrence)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>DOR</measure>
    <time_frame>24 months</time_frame>
    <description>Duration of response ,DOR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DCR</measure>
    <time_frame>24 months</time_frame>
    <description>Disease Control Rate，DCR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
    <time_frame>24 months</time_frame>
    <description>Progression free survival,PFS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>9month PFS rate</measure>
    <time_frame>9 months</time_frame>
    <description>Month 9 PFS rate,PFS9m</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>12month and 24 month OS rate</measure>
    <time_frame>24 months</time_frame>
    <description>Overall survival rate: the time from the date of icf to the date of documented clinical or radiological progression or death due to any cause within 12 and 24 months after first visit</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Biomarkers and ADA</measure>
    <time_frame>24 months</time_frame>
    <description>PD-L1、MSI、TMB expression and ADA</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Metastatic Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>SHR-1210+BP102+XELOX</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive SHR-1210 200mg,BP102 7.5mg/kg and oxaliplatin 130mg/m2 in day 1 intravenously every 3week, capecitabine by oral bid in day1-14 every 3 week until disease progression or unacceptable toxicity</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHR-1210</intervention_name>
    <description>200mg</description>
    <arm_group_label>SHR-1210+BP102+XELOX</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BP102</intervention_name>
    <description>7.5mg/kg</description>
    <arm_group_label>SHR-1210+BP102+XELOX</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oxaliplatin</intervention_name>
    <description>130mg/m2</description>
    <arm_group_label>SHR-1210+BP102+XELOX</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>capecitabine</intervention_name>
    <description>1000mg/m2</description>
    <arm_group_label>SHR-1210+BP102+XELOX</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥18 and ≤75 years old;&#xD;
&#xD;
          2. Histologically confirmed colorectal cancer with a metastatic / recurrent lesion that&#xD;
             cannot be cured by surgery.&#xD;
&#xD;
          3. At least one measurable lesion have been the confirmatory detection respect to RECIST&#xD;
             1.1&#xD;
&#xD;
          4. No prior first-line systemic anti-tumor therapy for mCRC (including systemic&#xD;
             chemotherapy, molecular targeted therapy, biotherapy, immunotherapy, radiotherapy,&#xD;
             local therapy and other study treatment) have been identified&#xD;
&#xD;
          5. At least 6 months have elapsed if considering the interval from the time of firstly&#xD;
             documented metastasis to the post-operational adjuvant chemotherapy termination&#xD;
&#xD;
          6. Can provide either a newly obtained or archival tumor tissue sample.&#xD;
&#xD;
          7. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1&#xD;
&#xD;
          8. Life expectancy ≥ 3 months&#xD;
&#xD;
          9. Subjects must have normal organ and marrow function as defined below:&#xD;
&#xD;
               1. Absolute neutrophil count (ANC) ≥1,500 /mm3（1.5×109 /L）&#xD;
&#xD;
               2. Platelets ≥90,000 / mm3（90×109 /L）&#xD;
&#xD;
               3. Hemoglobin ≥10 g/dL, within the 2 weeks prior to the screening no need for the&#xD;
                  transfusion&#xD;
&#xD;
               4. Serum albumin ≥2.8 g/dL&#xD;
&#xD;
               5. Total bilirubin≤ 1.5 X ULN, AST (SGOT), ALT (SGPT) ≤ 2.5 X ULN (AST/ALT ≤ 5 X ULN&#xD;
                  if liver metastatic);&#xD;
&#xD;
               6. Creatinine clearance ≥ 50 mL/min according to Cockcroft-Gault formula&#xD;
&#xD;
         10. For females of child bearing potential, a negative urine or serum pregnancy test&#xD;
             result within 72h before study treatment. Participants of reproductive potential must&#xD;
             be willing to use adequate contraception for the course of the study until 3 months&#xD;
             after the last dose of any of the drugs in the study.&#xD;
&#xD;
         11. The subjects are accredited with good compliance, signed the informed consent, and&#xD;
             capable to cooperate, completing the relevant examination and follow-ups.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Prior first-line systemic anti-tumor therapy for mCRC (including systemic&#xD;
             chemotherapy, molecular targeted therapy, immunotherapy, biotherapy, and other&#xD;
             treatment).&#xD;
&#xD;
          2. The metastatic/recurrent lesion is subject to be cured by surgical intervention.&#xD;
&#xD;
          3. Major operation or open biopsy or major trauma within 4 weeks prior to first dose.&#xD;
&#xD;
          4. Known Cerebral and/or leptomeningeal metastasis.&#xD;
&#xD;
          5. Bleeding predisposition, high bleeding risk or coagulant disorder, thrombotic event(s)&#xD;
             occurrence ≤6 months and/or hemoptysis ≤3 months (≥ 1/2 teaspoons fresh blood each)&#xD;
             prior to the screening; use of full dose oral or parenteral anticoagulant or&#xD;
             thrombolytic medication (allowing preventative anticoagulation); use of aspirin (&gt; 325&#xD;
             mg/day) or other platelet-inhibition non-steroidal anti-inflammatory drugs within 10&#xD;
             days since the screening; CT/MRI imaging evidence, testimony of the main&#xD;
             arteries/veins (such as pulmonary artery or superior vena cava) being infringed,&#xD;
             encroached&#xD;
&#xD;
          6. Subjects with uncontrolled hypertension and with a medical history of hypertensive&#xD;
             crisis or hypertensive encephalopathy; serious cardiovascular and cerebrovascular&#xD;
             diseases, including cerebrovascular accident (CVA) ≤6 months before the screening,&#xD;
             transient ischemic attack (TIA), myocardial infarction and significant vascular&#xD;
             disease (including but not limited to aortic aneurysms with need for surgical repair&#xD;
             or recent evidence of arterial thrombosis), unstable angina, heart failure and serious&#xD;
             arrhythmias that are uncontrolled by drugs (New York Heart Association Class ≥2).&#xD;
&#xD;
          7. Subjects with non-healing wounds, active peptic ulcer or fracture and active&#xD;
             infection; tracheal esophageal fistula, gastrointestinal perforation or&#xD;
             gastrointestinal fistula and abdominal abscess in the 6 months prior to the screening.&#xD;
&#xD;
          8. Subjects with any active autoimmune disease or history of autoimmune disease&#xD;
&#xD;
          9. Active infection or an unexplained fever &gt; 38.5°C before two weeks of randomization&#xD;
             (subjects with tumor fever may be enrolled at the discretion of the investigator);&#xD;
&#xD;
         10. History of Interstitial Pneumonia or received Corticosteroids for non-infectious&#xD;
             pneumonitis.&#xD;
&#xD;
         11. Known Human Immunodeficiency Virus (HIV) infection、active Hepatitis B or Hepatitis C.&#xD;
&#xD;
         12. Known history of hypersensitivity to macromolecular protein preparation or any&#xD;
             components of the SHR-1210 or BP102 formulation, allergy, hypersensitivity, or&#xD;
             contraindication to oxaliplatin, or Capecitabine&#xD;
&#xD;
         13. Currently participating or has participated in a study within 4 weeks of the first&#xD;
             dose of study medication.&#xD;
&#xD;
         14. Has a known additional malignancy within the last 5 years before study treatment with&#xD;
             the exception of curatively treated basal cell and squamous cell carcinoma of the skin&#xD;
             and/or curatively resected in-situ cervical and/or breast cancers&#xD;
&#xD;
         15. Received a live vaccine within 4 weeks of the first dose of study medication&#xD;
&#xD;
         16. Pregnancy or breast feeding.&#xD;
&#xD;
         17. According to the investigator, other conditions that may lead to stop the research.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Cancer Center of Sun-Yat Sen University (CCSYSU)</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>August 20, 2018</study_first_submitted>
  <study_first_submitted_qc>August 22, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 24, 2018</study_first_posted>
  <last_update_submitted>May 8, 2019</last_update_submitted>
  <last_update_submitted_qc>May 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 10, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SHR-1210</keyword>
  <keyword>BP102</keyword>
  <keyword>Phase II</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

